Results from a phase 1 study of the anti-immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 plus pembrolizumab in patients with previously treated advanced solid tumors

被引：0
|
作者：
Siu, Lillian L.
Gil-Martin, Marta
Cho, Byoung Chul
Perets, Ruth
Hilton, John
Geva, Ravit
Lugowska, Iwona
Gutierrez, Martin
Bonomi, Marcelo
Dziadziuszko, Rafal
Rasco, Drew
Ben-Ami, Eytan
Rodriguez, Cristina P.
Siddiqi, Shabana
Myer, Nicole
Suttner, Leah
Wilson, Douglas
Akala, Ombololaji O.
de Miguel, Maria
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT104
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT104
引用
收藏
页数：2
相关论文
共 50 条
  • [41] LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors-Results from the gastric cancer cohort.
    Chung, Hyun Cheol
    Lwin, Zarnie
    Gomez-Roca, Carlos
    Longo, Federico
    Yanez, Eduardo
    Alvarez, Eduardo Castanon
    Graham, Donna
    Doherty, Mark
    Cassier, Philippe
    Lopez, Juanita Suzanne
    Basu, Bristi
    Hendifar, Andrew Eugene
    Maurice-Dror, Corinne
    Gill, Sanjeev Singh
    Ghori, Razi
    Kubiak, Peter
    Jin, Fan
    Norwood, Kevin Glen
    Saada-Bouzid, Esma
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [42] Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)
    Naoya Yamazaki
    Tatsuya Takenouchi
    Manabu Fujimoto
    Hironobu Ihn
    Hiroshi Uchi
    Takashi Inozume
    Yoshio Kiyohara
    Hisashi Uhara
    Kazuhiko Nakagawa
    Hiroshi Furukawa
    Hidefumi Wada
    Kazuo Noguchi
    Takashi Shimamoto
    Kenji Yokota
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 651 - 660
  • [43] A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors
    Colin D. Weekes
    Muralidhar Beeram
    Anthony W. Tolcher
    Kyriakos P. Papadopoulos
    Lia Gore
    Priti Hegde
    Yan Xin
    Ron Yu
    L. Mason Shih
    Hong Xiang
    Rainer K. Brachmann
    Amita Patnaik
    Investigational New Drugs, 2014, 32 : 653 - 660
  • [44] A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors
    Weekes, Colin D.
    Beeram, Muralidhar
    Tolcher, Anthony W.
    Papadopoulos, Kyriakos P.
    Gore, Lia
    Hegde, Priti
    Xin, Yan
    Yu, Ron
    Shih, L. Mason
    Xiang, Hong
    Brachmann, Rainer K.
    Patnaik, Amita
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (04) : 653 - 660
  • [45] A phase 1 study of ABT-806, a humanized recombinant anti-EGFR monoclonal antibody, in patients with advanced solid tumors
    Cleary, James M.
    Yee, Lorrin Kwock-Chong
    Azad, Nilofer
    Carducci, Michael
    Cosgrove, David
    Limaye, Sewanti
    Gandhi, Leena
    Pedersen, Michelle
    Ansell, Peter
    Ames, William
    Sharma, Shringi
    Hsu, Ya-Hui
    Munasinghe, Wijith
    Reilly, Edward
    Holen, Kyle D.
    Humerickhouse, Rod
    CANCER RESEARCH, 2012, 72
  • [46] A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in patients (pts) with advanced solid tumors
    Weiss, Glen J.
    Luke, Jason J.
    Falchook, Gerald
    Eroglu, Zeynep
    Wang, Judy
    Hamilton, Erika
    Hecht, J. Randolph
    LoRusso, Patricia
    Eder, Joseph Paul
    Hughes, Lorraine
    Wang, Jing
    Running, Kelli
    McEachern, Kristen
    Bobilev, Dmitri
    Ribas, Antoni
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [47] Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)
    Yamazaki, Naoya
    Takenouchi, Tatsuya
    Fujimoto, Manabu
    Ihn, Hironobu
    Uchi, Hiroshi
    Inozume, Takashi
    Kiyohara, Yoshio
    Uhara, Hisashi
    Nakagawa, Kazuhiko
    Furukawa, Hiroshi
    Wada, Hidefumi
    Noguchi, Kazuo
    Shimamoto, Takashi
    Yokota, Kenji
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (04) : 651 - 660
  • [48] Final results from phase I, first-in-human, dose escalation study of a first-in-class anti-ILT2 antibody, SAR444881, alone and with pembrolizumab or cetuximab, in patients with advanced solid tumors
    Perets, R.
    Stemmer, S. M.
    Geva, R.
    Golan, T.
    Fakih, M.
    Cohen, J. E.
    Lieu, C.
    Jin, Z.
    Lorusso, P.
    Friedman, I.
    Hakim, M.
    Ziv, D. Haves
    Hashmueli, S.
    Mandel, I.
    Ben Moshe, T.
    Crawford, N.
    Abbadessa, G.
    Perez, R.
    Wu, M.
    Borad, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S675 - S675
  • [49] A biomarker study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in Phase 1a patients with previously treated solid tumors
    Cai, S.
    Brunner, A.
    Argast, G.
    Wang, M.
    Zhang, C.
    Kapoun, A.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E129 - E130
  • [50] FIRST-IN-HUMAN PHASE 1/2A STUDY OF THE NOVEL NONFUCOSYLATED ANTI-CTLA-4 MONOCLONAL ANTIBODY BMS-986218 ± NIVOLUMAB IN ADVANCED SOLID TUMORS: INITIAL PHASE 1 RESULTS
    Friedman, Claire
    Ascierto, Paolo
    Davar, Diwakar
    O'Hara, Mark
    Shapira-Frommer, Ronnie
    Dallos, Matthew
    Khemka, Vivek
    James, Lee
    Fischer, Bruce
    Demes, Shilpa
    Li, Li
    Kozicki, Martin
    Ravindran, Palanikumar
    Xu, Ke
    Kollia, Georgia
    Shoukry, Jacqueline
    Yunan, Mona
    Massey, Ashish
    Gutierrez, Martin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A239 - A239
12345